EP2292593A2 — Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
Assigned to Topotarget UK Ltd · Expires 2011-03-09 · 15y expired
What this patent protects
The present invention relates to compounds of the following formula, and pharmaceutically acceptable salts and solvates thereof, wherein: A is C 5-20 heteroaryl or C 5-20 carboaryl, and is optionally substituted; Q 1 is: a covalent bond, a saturated aliphatic C 1-7 alkylene grou…
USPTO Abstract
The present invention relates to compounds of the following formula, and pharmaceutically acceptable salts and solvates thereof, wherein: A is C 5-20 heteroaryl or C 5-20 carboaryl, and is optionally substituted; Q 1 is: a covalent bond, a saturated aliphatic C 1-7 alkylene group and is optionally substituted, or a partially unsaturated aliphatic C 2-7 alkylene group and is optionally substituted; R 1 is hydrogen, C 1-7 alkyl, or C 5-20 aryl; and, Q 2 is -(CH 2 ) n - where n is 4, 5, 6, or 7. The present invention also relates to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.
Drugs covered by this patent
- Beleodaq (belinostat) · Acrotech Biopharma
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.